ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Soleno Therapeutics, Inc. - SLNO - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Sept. 24, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ( "Soleno" or the "Company" ) SLNO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - ACADIA Pharmaceuticals ( NASDAQ:ACAD )
Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ( ACP-101 ) in patients with hyperphagia in Prader-Willi syndrome ( PWS ) .
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno ( SLNO ) To Contact Him Directly To Discuss Their Options Click here to participate in the action. NEW YORK, Sept. 18, 2025 ( GLOBE NEWSWIRE ) --
Soleno Therapeutics ( SLNO ) Drops Amid Critical Scorpion Report -- Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. SLNO experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an ...
Soleno Therapeutics ( SLNO ) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ( "Soleno" or the "Company" ) SLNO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Unpacking the Latest Options Trading Trends in Soleno Therapeutics - Soleno Therapeutics ( NASDAQ:SLNO )
Deep-pocketed investors have adopted a bearish approach towards Soleno Therapeutics SLNO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno ( SLNO ) To Contact Him Directly To Discuss Their Options
SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. ( NASDAQ: SLNO ) , You Are Encouraged to Contact The Rosen Law Firm About Your Rights - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Sept. 07, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc.
Bragar Eagel & Squire, P.C. Is Investigating Fortinet, Roblox, Soleno, and Simulations Plus and Encourages Investors to Contact the Firm - Fortinet ( NASDAQ:FTNT ) , Roblox ( NYSE:RBLX )
NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fortinet, Inc. FTNT, Roblox Corporation RBLX, Soleno Therapeutics, Inc. SLNO, and Simulations Plus, Inc.
Soleno Therapeutics to Participate in Upcoming September Conferences
REDWOOD CITY, Calif., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) ( NASDAQ: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in ...
Soleno Therapeutics ( SLNO ) Drops Amid Critical Scorpion Report -- Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. SLNO experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an investigation ...
SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno ( SLNO ) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO - Soleno Therapeutics ( NASDAQ:SLNO )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ( "Soleno" or the "Company" ) SLNO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Investigation of Soleno Therapeutics, Inc. ( SLNO ) Announced by Holzer & Holzer, LLC - Soleno Therapeutics ( NASDAQ:SLNO )
ATLANTA, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Holzer & Holzer, LLC is investigating whether Soleno Therapeutics, Inc. ( "Soleno Therapeutics" or the "Company" ) SLNO complied with federal securities laws.
Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics ( SLNO ) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Soleno Therapeutics ( SLNO ) Drops Amid Critical Scorpion Report -- Hagens Berman - Soleno Therapeutics ( NASDAQ:SLNO )
SAN FRANCISCO, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. SLNO experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an investigation ...
Soleno Under Serious Scrutiny As Short Seller Alleges PWS Drug Is Overpriced, Unsafe - Soleno Therapeutics ( NASDAQ:SLNO )
SLNO shares fall 9.68% after Scorpion Capital calls Vykat XR unsafe and overpriced. The report warns that Soleno's stock could drop back to penny-stock territory. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing.
How Much Upside is Left in Soleno Therapeutics ( SLNO ) ? Wall Street Analysts Think 43.15%
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Momentum in Soleno Therapeutics ( SLNO ) Should Keep going
Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Soleno ( SLNO ) Q2 Revenue Jumps 30%
Soleno Therapeutics ( NASDAQ:SLNO ) , a biotech company focused on rare disease treatments, posted its inaugural commercial revenue following the U.S. launch of VYKAT XR for Prader-Willi syndrome ( PWS ) . In its earnings release on August 6, 2025, the company reported GAAP revenue of $32.7 ...
Soleno Therapeutics, Inc. ( SLNO ) Reports Q2 Loss, Tops Revenue Estimates
Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Soleno Therapeutics, Inc. ( SLNO ) is a Great Momentum Stock: Should You Buy?
Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Soleno Therapeutics ( SLNO ) Climb 33.11% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Soleno Therapeutics (SLNO) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's What Could Help Soleno Therapeutics ( SLNO ) Maintain Its Recent Price Strength
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 ...
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( Nasdaq: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering ...
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( Nasdaq:SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common ...
Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025
REDWOOD CITY, Calif., July 10, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( Nasdaq: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the ...
Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress - Aardvark Therapeutics ( NASDAQ:AARD )
Aardvark's IPO raised $94.2 million at $16/share; funds expected to support operations into 2027. HC Wainwright initiated coverage with Buy rating, sets $40 price forecast of AARD. Get ahead of Wall Street reactions-Benzinga Pro delivers signals, squawk, and news fast. Now 60% off this 4th of July.
Soleno Therapeutics Highlights New Data on VYKAT ( TM ) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., June 25, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR ( diazoxide choline ) extended-release tablets, previously ...
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., June 20, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentations at the 2025 United In Hope: International ...
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome Organisation Conference is the first-ever international meeting jointly hosted by the ...
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., May 22, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application ( MAA ) seeking regulatory approval ...
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome
REDWOOD CITY, Calif., May 22, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) ( NASDAQ: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Soleno's Marketing Authorization Application ( MAA ) seeking ...
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT ( TM ) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., May 20, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc.
Soleno Therapeutics Announces Presentations Featuring VYKAT ( TM ) XR in Prader-Willi Syndrome at ISPOR 2025 - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., May 13, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data on the burden of Prader-Willi syndrome ( PWS ) and findings ...
Soleno Therapeutics Announces VYKAT ( TM ) XR Launch - Soleno Therapeutics ( NASDAQ:SLNO )
REDWOOD CITY, Calif., April 14, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( Soleno ) SLNO, a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the U.S. commercial availability of VYKAT™ XR ( diazoxide choline ) extended-release ...
Soleno Therapeutics Announces VYKAT ( TM ) XR Launch
First prescriptions delivered to individuals with PWS First prescriptions delivered to individuals with ...
Tesla To $455? Here Are 10 Top Analyst Forecasts For Monday - BILL Holdings ( NYSE:BILL ) , Agnico Eagle Mines ( NYSE:AEM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Susquehanna cut Saia, Inc. SAIA price target from $540 to $410.
Soleno Shares Are Up Today: What's Going On? - Soleno Therapeutics ( NASDAQ:SLNO )
Soleno Therapeutics shares jumped 37.2% after securing FDA approval for Vykat XR, its first commercial drug for treating hyperphagia. The approval was based on Phase 3 trial data showing significant effectiveness, with the drug expected to launch in the U.S. by April 2025.
Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results - Dermata Therapeutics ( NASDAQ:DRMA ) , Auddia ( NASDAQ:AUUD )
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 90 points on Thursday. The Dow traded down 0.23% to 42,358.68 while the NASDAQ fell 0.05% to 17,890.40. The S&P 500 also fell, dropping, 0.04% to 5,709.99. Consumer discretionary shares jumped by 1.2% on ...
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Avis Budget Gr ( NASDAQ:CAR ) , Concentrix ( NASDAQ:CNXC )
U.S. stocks were lower, with the Dow Jones index falling around 0.2% on Thursday. Shares of Concentrix Corporation CNXC rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.
Behind the Scenes of Soleno Therapeutics's Latest Options Trends - Soleno Therapeutics ( NASDAQ:SLNO )
Deep-pocketed investors have adopted a bearish approach towards Soleno Therapeutics SLNO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
Why Is Soleno Therapeutics Soaring On Thursday? - Soleno Therapeutics ( NASDAQ:SLNO )
FDA approved Soleno's Vykat XR, the first therapy for hyperphagia in Prader-Willi syndrome, for patients aged 4 and older. Soleno plans to launch Vykat XR in the U.S. by April 2025, supported by a strong commercial strategy and medical education efforts. Feel unsure about the market's next move?
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading.
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome - Soleno Therapeutics ( NASDAQ:SLNO )
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc.
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome ...
